GAO: Post-Vioxx, still no safety changes at FDA
December 9, 2009 by Maureen Martino
Three years after the Vioxx safety debacle, the FDA has yet to improve its drug safety oversight, according to Government Accountability Office findings. Vioxx was pulled from the market in 2004 after the drug was linked to an increased risk of heart attack and stroke. Two years later, the GAO, Institute of Medicine and other experts made recommendations to the FDA in order to prevent another Vioxx-like catastrophe.
bureaucracy, government, health, medicine, scandal
No comments:
Post a Comment